Detection of pancreatic cancer using antibody microarray-based serum protein profiling
Detection of pancreatic cancer using antibody microarray-based serum protein profiling
复制标题
DOI：
10.1002/pmic.200701167
复制
发表时间：
2008-06-01
期刊：
影响因子：
3.4
通讯作者：
Borrebaeck, Carl A. K.
中科院分区：
文献类型：
--
作者：
Ingvarsson, Johan;Wingren, Christer;Borrebaeck, Carl A. K.
癌蛋白质组学的驱动力是识别与特定恶性肿瘤相关的蛋白质特征。在这里，我们使用了重组单链抗体微阵列，试图对胰腺癌患者与健康受试者的血清进行分类。基于对未分级的、直接标记的全人血清蛋白质组的分析，我们已经确定了基于19种非冗余分析物的蛋白质特征，该蛋白质特征区分癌症患者和健康受试者。此外，可以定义由21种蛋白质分析物组成的潜在蛋白质签名，其显示与预期寿命为25岁的癌症患者相关。
The driving force behind oncoproteomics is to identify protein signatures that are associated with a particular malignancy. Here, we have used a recombinant scFv antibody microarray in an attempt to classify sera derived from pancreatic adenocarcinoma patients versus healthy subjects. Based on analysis of nonfractionated, directly labeled, whole human serum proteomes we have identified a protein signature based on 19 nonredundant analytes, that discriminates between cancer patients and healthy subjects. Furthermore, a potential protein signature, consisting of 21 protein analytes, could be defined that was shown to be associated with cancer patients having a life expectancy of